CTMX supply chain intelligence for CytomX Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CytomX Therapeutics, Inc. (CTMX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AMGN | Amgen Inc. | 90% | In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| AMGN | Amgen Inc. | 90% | Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to d… |
| BMY | Bristol-Myers Squibb Company | 90% | In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to discover and develop compounds for use in human therapeutics aimed at multiple imm… |
| MODERNA | MODERNA | 90% | In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditi… |
| ABBV | AbbVie Inc. | 80% | Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from ABBV g… |
| ABBV | AbbVie Inc. | 80% | For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement, and from time to time some of our research programs have been terminated by our partners. |
| ASTELLAS | ASTELLAS | 80% | In March 2026, Astellas chose to not advance the remaining preclinical programs under the alliance, resulting in a termination of the collaboration effective in the second quarter of 2026. |
| AZN | AstraZeneca PLC | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2… |
| CELG-RI | CELG-RI | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| LLY | Eli Lilly and Company | 72% | s while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved ind… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: s while the trials are conducted and … |
| MRK | Merck & Co., Inc. | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: ccess to our facility and initiate a work-from-home program limiting onsite activity to a substantially reduced level… |
| MYGN | Myriad Genetics, Inc. | 72% | ccess to our facility and initiate a work-from-home program limiting onsite activity to a substantially reduced level of laboratory research activities. Although we gradually increased our laboratory… |
| NKTR | Nektar Therapeutics | 72% | source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available when needed and could result in substant… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: source for their respective manufac… |
| NVSEF | Novartis AG | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSE… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 st… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, … |
| SNYNF | Sanofi | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| IMMUNOGEN | IMMUNOGEN | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| PFE | Pfizer Inc. | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| PFE | Pfizer Inc. | 70% | Reciprocal relationship from PFE graph: Reciprocal relationship from CTMX graph: Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna… |
| REGENERON | REGENERON | 70% | Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics. |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| REGENERON-PHARMACEUTICALS-INC | REGENERON-PHARMACEUTICALS-INC | 92% | the Agreement, with Regeneron Pharmaceuticals, Inc. (“Regeneron”), providing for the collaboration on the creation of conditionally-activated investigational bispecific cancer therapies |
| AMGN | Amgen Inc. | 90% | In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| AMGN | Amgen Inc. | 90% | Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into … |
| BMY | Bristol-Myers Squibb Company | 90% | In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the "BMS Agreement") to discover and develop compounds for use in human therapeutics aimed at multiple imm… |
| BMY | Bristol-Myers Squibb Company | 90% | Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from BMY grap… |
| MODERNA | MODERNA | 90% | In December 2022, we entered into a Collaboration and License Agreement (the "Moderna Agreement") with Moderna, pursuant to which we and Moderna will collaborate on the creation of mRNA-based conditi… |
| ABBV | AbbVie Inc. | 80% | Reciprocal relationship from ABBV graph: Reciprocal relationship from CTMX graph: For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| ABBV | AbbVie Inc. | 80% | For instance, in March 2023, AbbVie terminated our 2016 CD71 License and Collaboration Agreement |
| ASTELLAS | ASTELLAS | 80% | In March 2026, Astellas chose to not advance the remaining preclinical programs under the alliance, resulting in a termination of the collaboration effective in the second quarter of 2026. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| AZN | AstraZeneca PLC | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from CTMX graph: tol Myers Squibb amended the … |
| CELG-RI | CELG-RI | 72% | tol Myers Squibb amended the BMS Agreement and entered into Amendment Number 3 (“Amendment 3”), as previously amended by Amendment 1 and Amendment 2, to clarify the rights and restrictions of certain… |
| LLY | Eli Lilly and Company | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 stu… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we… |
| MRK | Merck & Co., Inc. | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| MYGN | Myriad Genetics, Inc. | 72% | and adverse effect on our business, financial condition, results of operations and prospects. Our employees and independent contractors may engage in misconduct or other improper activities, includin… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CTMX graph: and adverse effect on our business,… |
| NKTR | Nektar Therapeutics | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| NKTR | Nektar Therapeutics | 72% | Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NKTR g… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish… |
| NVSEF | Novartis AG | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from CTMX graph: Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 st… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Squibb was evaluating the safety and efficacy of BMS-986288 alone and in combination with nivolumab in a Phase 1/2 study in patients with certain advanced solid tumors. In February 2023, Bristol Myer… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish… |
| SNYNF | Sanofi | 72% | tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and… |
| AMGEN-ASTRAZENECA-PLC | AMGEN-ASTRAZENECA-PLC | 62% | h activities and efforts to establish and run clinical trials for Varseta-M and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and a… |
| AMGEN-NOVARTIS-AG | AMGEN-NOVARTIS-AG | 62% | h activities and efforts to establish and run clinical trials for Varseta-M and CX-801. However, in January 2025, we announced that we would reduce our workforce, primarily research and general and a… |
| BRISTOL-MYERS-SQUIBB-COMPANY | BRISTOL-MYERS-SQUIBB-COMPANY | 62% | rom Astellas was comprised of an upfront fee of $ 80.0 million and total potential contingent payments for development, regulatory and sales milestones of up to an aggregate of approximately $ 1.2 bi… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CTMX-DEBT | Debt stack $3.0M | 90% | Market cache reports total debt of $3.0M. |
| CTMX-DEBT-8909 | Warrants outstanding: 81620 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CTMX-OWNER-FMR-LLC | FMR LLC | 90% | 13F overlay lists FMR LLC as top holder; 183 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| SVA | Sinovac Biotech Ltd. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| BEAM | Beam Therapeutics Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['customer', 'supplier'] |